Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:4.1.1.6 (
CAD
)
4,420
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
This study aims to analyze the expression level and correlation of miR-182-5p and its target gene
PAPPA
in coronary atherosclerosis (
CAD
).Real time PCR, ELISA, and Western blotting methods were used to detect the expression levels. Dual-luciferase reporter gene assays were used to analyze the interaction between the 3'-UTR of
PAPPA
and miR-182-5p.The expression level of miR-182-5p in
CAD
was significantly lower than that in normal population, while the content of serum
PAPPA
was significantly increased, and the expression level of miR-182-5p was negatively correlated with the
PAPPA
content. The expression level of miR-182-5p decreased, while the expression level of
PAPPA
increased significantly in the ox-LDL treated HA-VSMC cells. Researchers found that
PAPPA
could promote the activation of IGF signaling pathway in HA-VSMC cells treated by ox-LDL, further activate NF-kB, PI3K/AKT and ERK signaling pathway, and promote cell proliferation. However, miR-182-5p could inhibit the expression of
PAPPA
, block the activation of IGF signal pathway, and inhibit the proliferation of HA-VSMC cells induced by ox-LDL. miR-182-5p had a targeted action site in the 3'-UTR of
PAPPA
by bioinformatics prediction. The analysis of luciferase reporter gene further confirmed that miR-182-5p could target the 3'-UTR of
PAPPA
to inhibit its expression.miR-182-5p demonstrated a protective effect on atherosclerosis and may be a potential therapeutic target for atherosclerosis.
...
PMID:MiR-182-5p Inhibits the Proliferation of Vascular Smooth Muscle Cells Induced by ox-LDL Through Targeting PAPPA. 3268 96
